ArticlePathologica2026
MesoRet: a reticulin stain-based deep learning algorithm to assist diffuse mesothelioma subtyping.
Article in Pathologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and validate a deep learning model trained on reticulin-stained whole slide images (MesoRet) to accurately identify transitional features and assist in the histologic subtyping of diffuse mesothelioma. Methods: A total of 115 cases of diffuse mesothelioma were collected from two institutions and reviewed by expert thoracic pathologists. Reticulin-stained whole-slide images were used to train a supervised deep learning model on the Aiforia Create platform to distinguish epithelioid, sarcomatoid, and transitional patterns. Model performance was validated on independent slides and compared with expert pathologists' assessments. Results: MesoRet accurately identified reticulin patterns across mesothelioma histotypes achieving 96.32% precision and 99.06% sensitivity, excluding artifacts and non-tumour tissue. It outperformed pathologists in identifying transitional patterns, reducing diagnostic time and minimising errors. Conclusions: MesoRet provides an accurate and objective approach for detecting reticulin patterns in mesothelioma, supporting histological subtyping and contributing to more consistent diagnoses. Although further validation is required, it represents a promising model to improve diagnostic precision and guide therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.